ICMR Says No Payment Made For Chinese Test Kits Supplies
The Hindu|April 28, 2020
Alleged profiteering by distributors supplying the kits

India does not stand to lose a single rupee, said the Indian Council of Medical Research (ICMR) on Monday in response to a clarification sought on the alleged profiteering by distributors, exposed through a legal dispute between an importer and a distributor, in the delivery of rapid antibody testing kits to it.

According to details provided in the Delhi High Court, the kits procured from China, whose delivered cost was ₹245 a test, were sold to ICMR for ₹600 a test — a mark up of 145%.

The matter came to light when Rare Metabolics Life Sciences Pvt Ltd and Aark Pharmaceuticals, distributors of Chinese Wondfo Biotech’s kits imported by Matrix Labs, approached the High Court recently to get delivery/payment disputes cleared. The Council, in a one-page clarification, noted that it had not made any payment whatsoever in respect of the supplies — “because of the due process followed (not going in for procurement with 100% advance amount)”.

Continue reading your story on the app

Continue reading your story in the newspaper

MORE STORIES FROM THE HINDUView All

Ministry Does U-Turn On Plasma Therapy

Treatment not proven: Health official

2 mins read
The Hindu
April 29, 2020

It's Wholesale Only At Koyambedu Market

Retail outlets to remain shut to bring down crowding.

2 mins read
The Hindu
April 29, 2020

U.S. May Seek Damages From China

President says many options on the table to hold Beijing accountable, draws an angry response

2 mins read
The Hindu
April 29, 2020

Trump's Bleach Statements Echo Claims By Pseudo-Scientists

‘Miracle cure’ quacks have long promoted industrial bleach to treat autism, malaria and many other medical conditions

3 mins read
The Hindu
April 29, 2020

‘Olympics Cancellation Likely If Vaccine Not Found In Time'

Further delays impossible, says Tokyo Games organising panel chief Mori

1 min read
The Hindu
April 29, 2020

ICMR Says No Payment Made For Chinese Test Kits Supplies

Alleged profiteering by distributors supplying the kits

2 mins read
The Hindu
April 28, 2020

Koyambedu Market May Be Shifted Out

Decision likely at today's meeting of stakeholders; aim is to enforce physical distancing

2 mins read
The Hindu
April 28, 2020

The Script Of Disruption And A New Order

Across the globe, the geopolitical and geo-economic fallout of the COVID-19 pandemic could be serious

6 mins read
The Hindu
April 28, 2020

A Policy Road Map To Tackle Covid-19

The interest of each and the interests of all now coincide, not only within nations but for all humanity

5 mins read
The Hindu
April 28, 2020

Massive Spike Of 522 Cases In Maharashtra

On Monday, cumulative tally surged to 8,590 positive cases with 27 more deaths

2 mins read
The Hindu
April 28, 2020
RELATED STORIES

टीका लेने वाले दस हजार लोगों में से 2 से 4 लोग संक्रमित

देश में टीका लेने के बाद भी 10,000 की आबादी में दो से चार लोग कोविड19 से संक्रमित हो गए ।

1 min read
Business Standard - Hindi
April 22, 2021

Low infection rate after vax, shot in the arm for inoculation drive

Post-vaccination breakthrough infection rate in India not more than 0.04%, says ICMR

2 mins read
The New Indian Express Chennai
April 22, 2021

Jab We Met

While the manufacturer of Covaxin got itself in a jam with Brazil following an inspection of its Hyderabad facility, AstraZeneca’s vaccine was put on hold in several nations after reports of blood clots. How safe are these vaccines?

7 mins read
India Legal
April 26, 2021

विदेशी टीके पर 3 दिन में फैसला

बाहरी टीके की उपलब्धता बढ़ाने के लिए कवायद तेज, तीन दिन में आयात लाइसेंस

1 min read
Business Standard - Hindi
April 16, 2021

भारत में अब कोविड-19 के तीन टीके लगाये जा सकते हैं, कुछ और के आने की संभावना

भारत के औषधि महानियंत्रक (डीसीजीआई) ने कुछ शर्तों के साथ कोविड-19 के रूसी टीके स्पूतनिक वी के देश में आपात इस्तेमाल की मंजूरी दे दी है और इसके साथ ही भारत में कोविशील्ड तथा कोवैक्सीन के बाद तीसरे टीके के उपयोग का रास्ता साफ हो गया है। इसके अतिरिक्त सरकार ने मंगलवार को अन्य टीकों के आपात इस्तेमाल को मंजूरी देने की प्रक्रिया भी तेज कर दी। टीकों के बारे में जानकारी निम्न प्रकार है।

1 min read
Samagya
April 14, 2021

कच्चे माल की कमी कोवैक्सीन के लिए चुनौती

हैदराबाद की टीका बनाने वाली कंपनी भारत बायोटेक कोवैक्सीन का उत्पादन बढ़ाने की कोशिश में लगी है मगर सूत्रों ने बताया कि उसे टीके में इस्तेमाल होने वाले एडजुवेंट की किल्लत से जूझना पड़ रहा है। एडजुवेंट का इस्तेमाल आम तौर पर टीके में प्रतिरक्षा क्षमता बढ़ाने के लिए किया जाता है।

1 min read
Business Standard - Hindi
April 15, 2021

EMISSIONS CONTROL IN THERMAL POWER STATIONS: A Long Road to Cross

In this article, Raghav Pachouri brings out the current situation and the challenges confronting us regarding emissions control in thermal power stations (TPSs) in India. While analysing the impact of the power sector on air pollution levels, he highlights the current status of compliance in India (especially Delhi-NCR and critically polluted areas) till June 2020 after revised emission norms for TPSs came into effect on December 7, 2015. He also dwells on the major roadblocks in the timely compliance of emission norms and also offers a few solutions.

7 mins read
Energy Future
January - March 2021

लॉकडाउन का बढ़ा खटका

मध्य प्रदेश में सप्ताहांत लॉकडाउन, एनसीआर में रात्रि कर्फ्यू

1 min read
Business Standard - Hindi
April 09, 2021

कार्यस्थल पर भी लग सकेंगे टीके

सरकारी व निजी दफ्तरों में 45 साल से अधिक उम्र के लोगों को कोविड टीका लगाने की अनुमति

1 min read
Business Standard - Hindi
April 08, 2021

India at risk, health infra could be swamped: Centre to states

‘Covid Situation Is Going From Bad To Worse’

6 mins read
The Times of India Delhi
March 31, 2021